About kidswell bio corp - GNTA
Genenta Science SpA operates as a biotechnology company, which engages in strategic consolidation focused on acquiring majority or full ownership of privately held, established companies operating in Italian national security-regulated sectors. Its activities and acquisition strategy span aerospace, defense, national security, including cybersecurity, and biotechnology and biosecurity. The company was founded by Pierluigi Paracchi, Bernhard Gentner, and Luigi Naldini on July 24, 2014 and is headquartered in Milan, Italy.
GNTA At a Glance
Genenta Science SpA
Via dell’Annunciata 31
Milan, Milan 20121
| Phone | 39-2-2900-1055 | Revenue | 0.00 | |
| Industry | Aerospace & Defense | Net Income | -7,369,418.77 | |
| Sector | Electronic Technology | Employees | 9 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GNTA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.361 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.706 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 1.705 |
GNTA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -818,824.308 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GNTA Liquidity
| Current Ratio | 14.155 |
| Quick Ratio | 14.155 |
| Cash Ratio | 13.291 |
GNTA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -27.913 |
| Return on Equity | -38.193 |
| Return on Total Capital | -21.311 |
| Return on Invested Capital | -31.016 |
GNTA Capital Structure
| Total Debt to Total Equity | 34.811 |
| Total Debt to Total Capital | 25.822 |
| Total Debt to Total Assets | 23.842 |
| Long-Term Debt to Equity | 34.811 |
| Long-Term Debt to Total Capital | 25.822 |